- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GenFleet Therapeutics (2595)
GenFleet Therapeutics stock price live, this page displays HK 2595 stock exchange data. View the 2595 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the GenFleet Therapeutics real time stock price chart below.
What Is the GenFleet Therapeutics Stock Price Today?
The GenFleet Therapeutics stock price today is 34.82.
What Is the Stock Symbol for GenFleet Therapeutics?
The stock symbol for GenFleet Therapeutics is "2595."
What Stock Exchange Does GenFleet Therapeutics Trade On?
GenFleet Therapeutics is listed and trades on the Hong Kong stock exchange.
Is GenFleet Therapeutics a Good Stock to Buy?
Determining whether GenFleet Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2595 quote. (ISIN: CNE1000074L2)
What Is the GenFleet Therapeutics Stock Price Today?
The GenFleet Therapeutics stock price today is 34.82.
What Is the Stock Symbol for GenFleet Therapeutics?
The stock symbol for GenFleet Therapeutics is "2595."
What Stock Exchange Does GenFleet Therapeutics Trade On?
GenFleet Therapeutics is listed and trades on the Hong Kong stock exchange.
Is GenFleet Therapeutics a Good Stock to Buy?
Determining whether GenFleet Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2595 quote. (ISIN: CNE1000074L2)
Hong Kong
Currency in HKD
34.82
-0.42(-1.19%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.88
36.30
52 wk Range
19.60
52.90
2595 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.8836.30
52 wk Range
19.6052.90
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2595 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
50.97
Upside
+46.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 50.97
(+46.38% Upside)
Earnings
Latest Release
Mar 24, 2026
EPS / Forecast
-1.94 / --
Revenue / Forecast
41.52M / --
Compare 2595 to Peers and Sector
Metrics to compare | 2595 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2595PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | −19.7x | −0.3x | |
PEG Ratio | 0.05 | −0.25 | 0.00 | |
Price/Book | 6.1x | 6.5x | 2.6x | |
Price / LTM Sales | 85.5x | 11.6x | 2.9x | |
Upside (Analyst Target) | 61.0% | 40.1% | 57.8% | |
Fair Value Upside | Unlock | −2.2% | 9.5% | Unlock |
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the GenFleet Therapeutics (2595) Stock Price Today?
The GenFleet Therapeutics stock price today is 34.82 HKD.
What Stock Exchange Does GenFleet Therapeutics Trade On?
GenFleet Therapeutics is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for GenFleet Therapeutics?
The stock symbol for GenFleet Therapeutics is "2595."
What Is the GenFleet Therapeutics Market Cap?
As of today, GenFleet Therapeutics market cap is 12.90B HKD.
What Is GenFleet Therapeutics's Earnings Per Share (TTM)?
The GenFleet Therapeutics EPS (TTM) is -6.07.
From a Technical Analysis Perspective, Is 2595 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has GenFleet Therapeutics Stock Split?
GenFleet Therapeutics has split 0 times.
What is the current trading status of GenFleet Therapeutics (2595)?
As of Jul 26, 2026, GenFleet Therapeutics (2595) is trading at a price of 34.82 HKD, with a previous close of 35.24 HKD. The stock has fluctuated within a day range of 33.88 HKD to 36.30 HKD, while its 52-week range spans from 19.60 HKD to 52.90 HKD.
What Is GenFleet Therapeutics (2595) Price Target According to Analysts?
The average 12-month price target for GenFleet Therapeutics is 50.97 HKD, with a high estimate of 61.89345686 HKD and a low estimate of 34.94151708 HKD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +46.38% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.